Nicox

2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021

Press Release

Nicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021

April 13, 2021 Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, informs its shareholders that the ordinary general meeting and the extraordinary general meeting convened on first call on Wednesday April 14, 2021, as closed meetings, without the physical presence of the shareholders, cannot be held as the quorum required by law will not be reached.

The shareholders of Nicox are thus convened on second call for an ordinary general meeting followed by an extraordinary general meeting on the same resolutions and the same agenda on Wednesday April 28, 2021 at 2:00 pm CET, as closed meetings, without the physical presence of the shareholders.

The documents mentioned in articles R.22-10-23 of the French Code de commerce, including those to be presented at the general meetings, are available on the Company's website www.nicox.com.

The ordinary general meeting and the extraordinary general meeting of April 14, 2021 acknowledging the lack of quorum, will be broadcasted live and recorded in audio format on Nicox’s website www.nicox.com. The Chief Executive Officer of Nicox, upon delegation by the Board of Directors on February 26, 2021, appointed Ms. Brigitte Duquesroix and Ms. Irène Lalande as scrutineers.

Shareholders may vote at the general meetings of April 28, 2021 ahead of these meetings by correspondence or by proxy, by post or electronically. All the information relating to the voting process can be found on the Company's website. Shareholders may also contact the Investor Relations team at [e-mail] for any question on the voting process. The proxy forms sent by correspondence or the electronic votes for the general meetings of April 14, 2021 remain valid for the general meetings of April 28, 2021. About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.  Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.